Two Sigma Investments LP Acquires Shares of 104,184 OptiNose Inc (OPTN)
Two Sigma Investments LP acquired a new position in shares of OptiNose Inc (NASDAQ:OPTN) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 104,184 shares of the company’s stock, valued at approximately $646,000.
Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of OptiNose by 8.0% during the 3rd quarter. BlackRock Inc. now owns 1,076,798 shares of the company’s stock worth $13,384,000 after purchasing an additional 79,541 shares in the last quarter. Kornitzer Capital Management Inc. KS grew its holdings in shares of OptiNose by 1,262.9% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 477,005 shares of the company’s stock worth $2,957,000 after purchasing an additional 442,005 shares in the last quarter. Broadfin Capital LLC acquired a new stake in shares of OptiNose during the 4th quarter worth $4,406,000. JPMorgan Chase & Co. grew its holdings in shares of OptiNose by 39.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,874,231 shares of the company’s stock worth $23,297,000 after purchasing an additional 526,501 shares in the last quarter. Finally, Vanguard Group Inc grew its holdings in shares of OptiNose by 1.6% during the 3rd quarter. Vanguard Group Inc now owns 779,689 shares of the company’s stock worth $9,691,000 after purchasing an additional 12,404 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.
OPTN has been the topic of several analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $27.00 target price on shares of OptiNose in a report on Monday, February 4th. Zacks Investment Research raised OptiNose from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. ValuEngine lowered OptiNose from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Royal Bank of Canada reduced their target price on OptiNose to $25.00 and set an “outperform” rating on the stock in a report on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $28.00.
OptiNose (NASDAQ:OPTN) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.20. The business had revenue of $3.02 million for the quarter, compared to analyst estimates of $2.60 million. OptiNose had a negative return on equity of 77.32% and a negative net margin of 1,509.87%. Equities analysts predict that OptiNose Inc will post -2.86 EPS for the current fiscal year.
WARNING: “Two Sigma Investments LP Acquires Shares of 104,184 OptiNose Inc (OPTN)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/two-sigma-investments-lp-acquires-shares-of-104184-optinose-inc-optn/2952936.html.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Recommended Story: Short Selling Stocks and Day Traders
Want to see what other hedge funds are holding OPTN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptiNose Inc (NASDAQ:OPTN).
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.